Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.36 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.36 |
| ▸ | CTSS | P25774 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13330836 | 0.91 | CTSB (0.53) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13330867 | 0.87 | CTSB (0.46) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL8160817 | 0.82 | CTSB (0.63) | CYP3A4CTSBCTSS | |
| SCHEMBL13330896 | 0.82 | CTSB (0.50) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL8251514 | 0.82 | CYP3A4 (0.46) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13330833 | 0.81 | CTSB (0.59) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13330841 | 0.79 | CTSB (0.55) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL13330820 | 0.78 | CTSB (0.45) | CYP3A4CTSBADRB3ADRA2BADRA2C | |
| SCHEMBL8162555 | 0.78 | CYP3A4 (0.38) | CYP3A4CTSB | |
| SCHEMBL13330966 | 0.77 | CTSB (0.61) | CYP3A4CTSBCTSS |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-8937080-B2 | Pyrimidine substituted macrocyclic HCV inhibitors | MEDIVIR AB (SE) | 2015-01-20 | — | — | US | disclosed |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2010-05-06 | — | — | US | disclosed |
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | TIBOTEC PHARMACEUTICALS, LTD. (IE) | 2010-05-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100113440-A1 | PYRIMIDINE SUBSTITUTED MACROCYCLIC HCV INHIBITORS | NUDT1, PNP, SLC28A1 | CYP3A4 318/4885CTSB 2141/4885ADRB3 2926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.